The trajectory of Viagra presents a complex case for stakeholders in the medicinal sector. While initially a phenomenal success, producing billions, the exclusivity end and the subsequent flood of off-brand alternatives have drastically impacted income. This presents questions about the ongoing sustainability of related therapeutic projects and sug